ATE138196T1 - Testverfahren für und behandlung von autoimmunkrankheiten - Google Patents

Testverfahren für und behandlung von autoimmunkrankheiten

Info

Publication number
ATE138196T1
ATE138196T1 AT90906028T AT90906028T ATE138196T1 AT E138196 T1 ATE138196 T1 AT E138196T1 AT 90906028 T AT90906028 T AT 90906028T AT 90906028 T AT90906028 T AT 90906028T AT E138196 T1 ATE138196 T1 AT E138196T1
Authority
AT
Austria
Prior art keywords
treatment
autoimmune diseases
testing
diseases
diagnosis
Prior art date
Application number
AT90906028T
Other languages
English (en)
Inventor
Michael Daniel Cahalan
Kanianthara George Chandy
Stephen Grissmer
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE138196T1 publication Critical patent/ATE138196T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT90906028T 1989-03-06 1990-03-05 Testverfahren für und behandlung von autoimmunkrankheiten ATE138196T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31949989A 1989-03-06 1989-03-06

Publications (1)

Publication Number Publication Date
ATE138196T1 true ATE138196T1 (de) 1996-06-15

Family

ID=23242496

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90906028T ATE138196T1 (de) 1989-03-06 1990-03-05 Testverfahren für und behandlung von autoimmunkrankheiten

Country Status (10)

Country Link
EP (1) EP0463114B1 (de)
JP (1) JPH04504173A (de)
AT (1) ATE138196T1 (de)
CA (1) CA2049007A1 (de)
DE (1) DE69027025T2 (de)
FI (1) FI914160A0 (de)
IE (1) IE900786L (de)
NO (1) NO913499L (de)
PT (1) PT93337B (de)
WO (1) WO1990010871A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2181677T3 (es) * 1991-08-23 2003-03-01 Univ Nebraska Metodo y composiciones utiles en la reprogramacion celular.
WO1996010091A1 (en) * 1994-09-29 1996-04-04 Merck & Co., Inc. A high capacity screen for immunoregulants
GB9520411D0 (en) * 1995-10-06 1995-12-06 Wales College Of Medicine Method of testing
WO1999048927A1 (en) * 1998-03-25 1999-09-30 Cornell Research Foundation, Inc. Methods for designing specific ion channel blockers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0407399A4 (en) * 1988-02-03 1991-06-19 Xoma Corporation Immunosupression with anti-pan t-cell immunotoxin compositions
EP0397798A4 (en) * 1988-02-03 1991-10-30 Xoma Corporation Therapeutic use of anti-t cell immunotoxin for autoimmune diseases

Also Published As

Publication number Publication date
EP0463114A4 (en) 1992-01-22
NO913499D0 (no) 1991-09-05
NO913499L (no) 1991-09-05
DE69027025T2 (de) 1996-10-24
JPH04504173A (ja) 1992-07-23
PT93337B (pt) 1997-01-31
WO1990010871A1 (en) 1990-09-20
FI914160A0 (fi) 1991-09-03
EP0463114A1 (de) 1992-01-02
PT93337A (pt) 1990-11-07
DE69027025D1 (de) 1996-06-20
CA2049007A1 (en) 1990-09-07
EP0463114B1 (de) 1996-05-15
IE900786L (en) 1990-09-06

Similar Documents

Publication Publication Date Title
Lies et al. Relative T‐cell specificity of lymphocytotoxins from patients with systemic lupus erythematosus
ATE255902T1 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv- verwandten krankheiten
ES2132063T3 (es) Procedimiento para la captura y recuperacion de celulas.
ATE315654T1 (de) Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen
ES2075050T3 (es) Peptidos que tienen actividad cooperadora de celulas t.
TR199901971T2 (xx) Bir resept�re ba�lanan peptidler ve bile�ikler.
ES2133813T3 (es) Cadenas de lamininas: diagnostico y uso terapeutico.
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
ATE6032T1 (de) Biologisch aktive substanzen, deren herstellung aus menschlichem kasein und zubereitungen, die sie enthalten.
ES2172287T4 (es) Metodos de deteccion y tratamiento de individuos con celulas anormales que expresan los antigenos peptidicos hla-a2/tirosinasa.
IT8026366A0 (it) Composizione termostabile formatrice di polimero e suo impiego negli esami diagnostici di sostanze biologiche.
ATE138196T1 (de) Testverfahren für und behandlung von autoimmunkrankheiten
CA2070647A1 (en) Use of an anticoagulant as a diagnostic agent
ATE125870T1 (de) Hiv-spezifische monoklonale antikörper und hybridome zu ihrer herstellung.
DE58908628D1 (de) Mittel für immunchemische Tests, carboxylgruppenhaltige Polymere enthaltend.
Hong Update on the immunodeficiency diseases
DE3784468D1 (de) Testbares mehrmodus-zaehlernetz und methode zur durchfuehrung des tests.
ATE178074T1 (de) Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes
WUEPPER et al. Serologic tests for syphilis and the false-positive reactor
BR8700693A (pt) Expelentes de microbios fitopatogenicos e composicao expelente de microbios fitopatogenicos
BG28719A3 (en) Method of obtaining of 17- alfa- (3- iodinebenzoiloxy)- 9 alfa chloride- 4- pregnen 3,20- dions and their alfa- homoanaloges
Nuti et al. Circulating immune complexes detected by Clq solid phase assay in leprosy
Thompson Sexual Promiscuity
Chapman et al. Do parathyroid and adrenal autoantibodies coexist?
Hawley et al. The effect of divalent cation chelators and magnesium on activation of the alternative complement pathway by Fusobacterium polymorphum (nucleatum)